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The amount of coronary artery calcification increases with age and the 
presence of cardiovascular risk factors and comorbidities.1,2 Up to 20% 
of percutaneous coronary intervention (PCI) procedures are challenged 
by severe calcifications, and coronary calcifications have been shown 
to be an independent predictor of PCI failure and future adverse 
cardiac events.3,4 Lesion calcification increases procedural complexity 
and time. More specifically, calcium localisation (superficial or deep), 
distribution (focal, circumferential and longitudinal extension) and 
thickness influence procedural success, stent delivery and deployment.5 
Several techniques to treat calcified lesions in native coronary arteries 
are available, including high-pressure and super-high pressure non-
compliant balloons, cutting/scoring balloons, atherectomy devices, 
both rotational and orbital, and excimer lasers.6 These devices rely on 
tissue compression and or tissue debulking, and have higher rates of 
procedural complications, such as dissections, perforations and distal 
embolisation. Moreover, their success rate is reduced when deep, thick 
or eccentric calcifications are present, and the induced tissue injury 
might accelerate uncontrolled neointimal growth and restenosis.6,7 
So far, neither specialty balloons nor atherectomy devices have been 
proved to be superior to high-pressure non-compliant balloons in 
improving clinical outcomes.8,9
Recently, an alternative way to disrupt calcium has been developed 
that is based on the lithotripsy concept used to treat kidney 
and ureteral stones. The Intravascular Lithotripsy (IVL) System 
(Shockwave Medical) transforms electrical energy into mechanical 
energy during low-pressure balloon inflation.10 The technology does 
not rely on direct vascular tissue injury for plaque modification but 
on sonic waves, which travel from the balloon-based catheter to 
the surrounding tissue with the intention of safely and selectively 
breaking both superficial and deep calcium deposits with minimal 
soft tissue impairment, while improving vessel compliance. In 
contrast to debulking techniques, the calcium fragments resulting 
from the IVL therapy remain in situ, reducing the likelihood of distal 
embolisation. The safety and efficacy of the IVL with minimal vessel 
injury was demonstrated in prospective single-arm studies, where 
moderate to severely calcified lesions in peripheral artery disease 
were tackled; these were the Shockwave Lithoplasty Disrupt Trial 
for PAD 1 and 2 (Disrupt PAD 1 and 2) and Safety and Feasibility of 
the Shockwave Lithoplasty® System for the Treatment of Peripheral 
Vascular Stenosis (BTK) trials.11-14 
The Coronary Intravascular Lithotripsy System
The Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I), a 
multicentre, prospective, single-arm study conducted in seven centres 
in Europe and Australia, was the first to assess the safety and efficacy 
of the Shockwave Coronary IVL in 60 patients with severe (100%) 
calcified lesions in native coronary arteries before drug-eluting stent 
implantation. The balloon was successfully delivered in 59 patients and 
stent implantation was successful in all cases, with no major procedural 
complications, such as slow flow, no reflow, distal embolisation or 
perforation reported. Device delivery was facilitated by pre-dilatation 
with a small balloon in 37% of patients. Clinical success was 95%, 
defined as residual diameter stenosis <50% without in-hospital major 
cardiac adverse events (MACE; a composite of death, MI and target-
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vessel revascularisation) at 30 days; MACE at 6 months increased to 
8.5% with three non-Q wave MI events within the first 30 days and two 
cardiac deaths.15 
An optical coherence tomography sub-study in 31 patients in the 
Disrupt CAD I trial confirmed the effects of IVL on the vessel wall.16 
Calcium fractures were evident in 42.9% of the lesions and multiple 
circumferential cracks in the same cross-sectional area were witnessed 
in more than 25% of the cases, with a higher incidence of fractures in 
heavier calcified plaques (highest tertile versus lowest tertile; p=0.009). 
The presence of calcium ruptures allowed to increase acute lumen 
gain (mean acute area gain = 2.1  mm2) independently of the degree 
of calcification, enabling successful stent implantation with uniform 
expansion. Coronary dissections (type B or greater) occurred in four 
cases during angioplasty and were successfully treated with stent 
implantation; no other procedural complications were reported. This 
data provided the first results encouraging the use of the Shockwave 
Coronary IVL for the treatment of calcified lesions in the coronary 
vasculature. Following these findings, the device received European CE 
mark approval in May 2017 for commercial use. 
The findings of Disrupt CAD I were further confirmed in a small (n=26) 
real-world study including patients with both stable and unstable 
disease, either as an upfront calcium modification technique or as 
a bailout after suboptimal results with standard balloon dilatation. 
Angiographic success occurred in all cases (<20% residual stenosis) 
without procedural complications.17 
At present, the results of the Disrupt CAD II (post-market prospective, 
multicentre, single-arm study), which enrolled 120 patients across 
Europe, are pending. More recently, the Disrupt CAD III study was 
announced. The study will aim to enrol 392 patients in 50 centres 
across the US and Europe with the intention to obtain Food and Drug 
Administration (FDA) approval. 
The available studies and case reports on the use of coronary IVL are 
summarised in Table 1. 
The System 
The Coronary IVL System consists of a portable, rechargeable generator, 
a connector cable with a push button to allow manually controlled 
delivery of electric pulses, and a 6 Fr compatible, rapid-exchange, 
semi-compliant balloon catheter to be used following standard 
angioplasty practice over a 0.014" guidewire (Figure 1).
The semi-compliant balloon integrates two radiopaque lithotripsy 
emitters 6 mm apart and two conventional markers at the proximal 
and distal edges of the balloon. These emitters receive electrical 
pulses from the generator vaporising the fluid (a standard mixture 
of 50% NaCl 0.9% and 50% radiopaque contrast) within the balloon 
and creating a rapidly expanding and collapsing bubble. This bubble 
can transmit unfocused circumferential pulsatile mechanical energy 
into the vessel wall, in the form of sonic pressure waves equivalent 
to approximately 50 atmospheres (atm). The balloons are available 
in diameters ranging from 2.5 mm to 4.0 mm with a standard 
length of 12 mm (Table 2); their crossing profiles range from 0.043" 
to 0.046" (Figure 2). 
The IVL therapy consists of a series of 10 pulses (1 cycle) or 10 
seconds (1 pulse per second). The number of therapies needed per 
lesion will depend on lesion resistance; however, the maximum 
number of pulses to be delivered by each individual catheter is limited 
to 80 pulses (eight cycles). 
Intravascular Lithotripsy Procedure
The IVL procedure does not require high-level additional training for 
interventional cardiologists. The shockwave balloon must be sized 
accordingly to the reference vessel diameter (ratio 1:1), placed in the 
target calcified lesion and inflated up to 4 atm to ensure apposition to 
the vessel wall; the lithotripsy emitters are then activated to deliver the 
acoustic pulses by pushing the button on the connector cable. Once 
a cycle of 10 pulses has been delivered, the balloon can be inflated 
up to 6 atm (nominal pressure) to increase balloon compliance and to 
assess symmetrical expansion, confirming calcium modification. Next, 
the balloon is deflated carefully to allow small air bubbles to escape. 
The previous steps must be repeated for each intended IVL cycle and 
at least two IVL cycles are recommended to treat the target area. For 
the treatment of lesions longer than 12 mm, the catheter needs to 
be repositioned and overlapping treatment areas might occur. See 
Supplementary Videos 1–4.
Due to the slightly higher profile of the shockwave catheter, pre-
dilatation with standard balloons might be necessary in some cases 
to facilitate deliverability and positioning, especially when lumen 
reduction is severe. Notwithstanding this, the balloon allows the use 
of guide-catheter extenders and buddy-wire support.18 Furthermore, 
although the system is labelled 6 Fr compatible, it could be used 
with a 5 Fr guiding catheter where the radial artery is small.19 The 
use of dilatation with non-compliant balloons after IVL, although 
not mandatory, could be considered to expand the lumen further. 
Moreover, aggressive plaque modification devices such as cutting/
scoring balloons or atherectomy could be used as adjuvant therapy in 
challenging lesions to improve results.20 
Potential Uses
At present, the instructions for use of the Shockwave Coronary IVL 
System restrict its use to lesion preparation in native coronary arteries 
(Figure 3). Given it is assumed to be safer than previous approaches, 
the number of case reports and small case series reporting on its use 
in more challenging scenarios is increasing. 
Acute Coronary Syndromes
Calcified lesions in culprit vessels are common in patients presenting 
with acute coronary syndromes (moderate calcification is found 
26.1% of these patients and severe calcification in 5.9%), and their 
presence is a strong predictor of definite stent thrombosis (HR 1.62; 
95% CI [1.14–2.30]; p=0.007) and target lesion revascularisation (HR 
1.44; 95% CI [1.17–1.78]; p<0.001).1 The Disrupt CAD study included 
only patients with stable and unstable angina. Although there is not 
enough evidence to support the use of the IVL during primary PCI, early 
experience has shown favourable results.17,21
Unprotected Left Main Calcified Stenosis
PCI has become an option for the treatment of left main (LM) disease, 
with a class IA recommendation for patients with a SYNTAX score 
≤22 and class IIA for a SYNTAX score 23–32.22 Calcification increases 
procedural complexity and therefore the risk of complications. Although 
atherectomy has previously been proposed as a valid and feasible 
option, the high-risk profile of those patients means safer approaches 
would be welcome.23,24 
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The Coronary IVL System, with controlled pulses delivered under low 
pressure, might potentially improve plaque modification with a lower 
risk of vessel closure, perforation or embolisation.25 
Chronic Total Occlusions
Moderate to severe calcification is frequently found in chronic total 
occlusions, and debulking devices are usually avoided because the 
procedure is difficult and has a high risk of complications; where standard 
balloons fail, the Coronary IVL System might be useful in facilitating lumen 
dilatation and communication with the subintimal space.26,27
Stent Underexpansion due to Underlying Calcification
Although the technique has been developed to treat calcified lesions 
in native coronary arteries before stenting, patients with severe stent 
underexpansion because of heavy calcification are at a higher risk of 
stent failure and future adverse events. Until now, undilatable lesions 
in previously stented segments have been courageously approached 
with debulking devices such as cutting balloons and atherectomy, 
with unpredictable results and risks of procedural complications and 
stent damage.28–31 
Of note, the effectiveness of those techniques is limited by the 
presence of metallic struts, and deeper calcifications therefore remain 
unaffected. The circumferential sonic waves of the Coronary IVL 
System, conversely, have the advantage of extending beyond strut 
layers and fracture deeper calcium deposits (Figure 4). Several case 
reports have supported the use of the technology for optimising stent 
expansion without complications.32–39 
Of note, the efficacy of the system in segments with multiple layers of 
stents has not been demonstrated and its impact on stent backbone/
polymer integrity and drug elution is still unknown. Nonetheless, at 
present, there are no alternative percutaneous options for patients left 
with underexpanded stents due to heavy calcification. 
Effects on Cardiac Rhythm
Electric signals similar to pacing spikes on the electrocardiogram 
(ECG) tracing during pulse-delivery have been described.17,40–42 These 
so-called ‘shocktopics’ and asynchronous cardiac pacing have been 
reported in up to 77.8% of the cases, with a 16-fold increased 
risk in patients with a heart rate <65 BPM. Cardiac pacing has not 
been linked to any specific number of IVL cycles or coronary artery 
anatomy, although its frequency is higher when either the left anterior 
descending artery or the right coronary artery are treated.42
The exact mechanism behind this phenomenon is still unclear. 
A potential explanation might be that the transformed mechanical 
energy reaches and couples with the cardiac conduction system 
producing ectopic atrial and or ventricular captures.43 Although no 
relevant clinical events have been reported, it warrants paying special 
attention to ECG and aortic pressure waveforms changes during 
IVL administration; the resulting VOO pacing mode is theoretically 
Figure 1: Shockwave Coronary Intravascular Lithoplasty 
System
Generator
Connector cable
Lithotripsy catheter
(6 Fr compatible)
Push button
Source: Adapted with permission from Shockwave Medical.
Table 2: Intravascular Lithotripsy Balloon Sizes and Compliance for Coronary Intervention
Pressure (atm) Balloon size
2.5 × 12 mm 2.75 × 12 mm 3.0 × 12 mm 3.25 × 12 mm 3.5 × 12 mm 3.75 × 12 mm 4.0 × 12 mm
4 (IVL) 2.4 2.6 2.9 3.2 3.4 3.7 3.8
5 2.4 2.7 2.9 3.2 3.4 3.7 3.8
6 (NP) 2.5 2.7 2.9 3.2 3.4 3.7 3.9
7 2.5 2.7 3.0 3.3 3.5 3.8 3.9
8 2.5 2.7 3.0 3.3 3.5 3.8 4.0
9 2.5 2.8 3.1 3.3 3.5 3.9 4.1
10 (RBP) 2.5 2.8 3.1 3.4 3.6 3.9 4.1
atm = atmospheres; IVL = intravascular lithotripsy; NP = nominal pressure; RBP = rated burst pressure.
Figure 2: Intravascular Lithoplasty Therapy
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pro-arrhythmic (potential R on T phenomenon) and, until further 
data become available, pacemaker carriers should be assessed for 
inappropriate device sensing during the IVL cycles and to ensure 
correct pacing function post-procedure. Further investigation in the 
matter will be provided by the substudies in the Disrupt CAD III trial.
Challenging Lesions
Some lesions might respond better to IVL therapy than to other plaque 
modification approaches. Reports have pointed out the usefulness 
of the IVL therapy on creating calcium fractures as assessed with 
intravascular ultrasound, and achieving optimal stent expansion in 
undilatable lesions that have been resistant to specialty balloons and 
rotational atherectomy.44–46 
In contrast, some lesions might not be suitable for IVL treatment or may 
remain resistant after the application of all 80 pulses. Severe tortuosity or 
angulation, critical lumen reduction, plaque indentation into the lumen 
and a very low vessel expansion compliance (small vessels and multiple 
stent layers present), could impact balloon deliverability and positioning. 
Up to 46% of the lesions might also require dedicated lesion pre-
dilatation and/or post-dilatation with non-compliant balloons or could 
benefit from adjuvant lesion preparation with conventional devices such 
as specialty balloons or atherectomy to either facilitate balloon delivery 
or increase calcium compliance after lithotripsy therapy.17,45 
Figure 4: Intravascular Lithotripsy Therapy Effect on Stent 
Underexpansion due to Calcified Lesion
Figure 3: Intravascular Lithoplasty Therapy: Effect on Heavy Calcified Coronary Lesions
LA = 2.92 mm2 LA = 6.34 mm2
A B
C D
Post-shockwave
(complete balloon expansion)
Pre-shockwave
(dog bone effect)
LA = 2.55 mm2 LA = 6.15 mm2 LA = 8.32 mm2
A B C
D E F
Pre-shockwave Post-shockwave Post-stenting
Fluoroscopy: A: before intravascular lithotripsy (IVL); B: after IVL. Red arrow shows ‘dog bone’ 
effect. Optical coherence tomography: C: before IVL d: after IVL. Asterisks show calcium 
deposits in the vessel wall. Arrows show calcium fractures. LA = lumen area.
Angiography left anterior descending coronary artery: a: before intravascular lithotripsy (IVL); b: after IVL; c: after stenting. Red arrow shows severe calcification. Optical coherence 
tomography: d: before IVL; e: after IVL; f: after stenting. Asterisks show calcium deposits in the vessel wall. Arrows show calcium fractures. LA = lumen area.
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While balloon rupture is uncommon, it can cause vessel complications. 
Case reports have described sudden IVL balloon burst during lithotripsy 
therapy with important vessel dissection; however, it is fair to highlight 
that either critical stenosis or severe vessel tortuosity were present, 
which suggests that, in some anatomies, the IVL system might not be 
suitable or should be used with caution.47,48 
Furthermore, vessels with a diameter >4 mm (maximum shockwave 
balloon size) or important plaque eccentricity preclude appropriate IVL 
balloon apposition to the vessel wall, and may reduce the efficacy of the 
therapy. More data are needed on the specific efficacy of IVL in concentric 
versus eccentric lesions. In the Disrupt CAD study, 22% of the patients had 
eccentric plaques; nevertheless, overall device success was 98%.15
 
Moreover, performing intracoronary imaging where important coronary 
calcification is suspected during the angiographic assessment could 
help to accurately assess calcium distribution, localisation and 
thickness. The use of intracoronary imaging before and after lithotripsy 
therapy could not only assist the appropriate selection of IVL balloon 
sizes but also potentially help to identify IVL responders and identify 
patients who might need adjuvant therapy from other plaque-
modification devices .
Further clinical data are needed to assess the implications of patient, 
vessel and lesion characteristics on the effectiveness of this therapy, 
the need for further adjuvant therapy with conventional devices and 
potential complications. 
Conclusion
The Coronary IVL System is a promising new treatment modality to 
tackle moderate to severe calcified coronary lesions, with a high rate 
of success and a low risk of complications. Larger studies and longer-
term clinical data are needed to confirm the safety and efficacy of this 
technique with special attention to the effects on cardiac conduction 
and vessel healing response. Randomised controlled clinical trials are 
required to evaluate its superiority against currently available calcium-
modifying devices.
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